An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin (Q73510238)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 1995

Language	Label	Description	Also known as
English	An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin	scientific article published on 01 January 1995

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin (English)

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

tetrahydroisoquinolines

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

7

object named as

Sawyer WH

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

M. Manning

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

L. L. Cheng

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

S. Stoev

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

K. Bankowski

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

J. Przybyiski

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

W. A. Klis

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

W. H. Sawyer

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

N. C. Wo

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

W. Y. Chan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9222985

7 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9222985

7 November 2024

publication date

1 January 1995

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

January 1995

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9222985

7 November 2024

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpsc.310010109

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psc.310010109

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Journal of Peptide Science

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

66-79

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations

1

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Über die Bildung von Isochinolin-derivaten durch Einwirkung von Methylal auf Phenyl-äthylamin, Phenyl-alanin und Tyrosin

2

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Angiotensin converting enzyme inhibitors: N-Substituted monocyclic and bicyclic amino acid derivatives

4

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors

8

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analog: effects on receptor selectivity and stereospecificity

9

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity

10

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies

12

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Conformationally restricted analogs of oxytocin; stabilization of inhibitory conformation

13

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism

15

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin

16

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin

17

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

[1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response t

18

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin

19

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin

20

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Solid-phase synthesis and some pharmacological properties of deamino-4-threonine analogs of the vasopressins and vasotocin and [deamino]arginine-vasotocin

21

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Solid-phase synthesis of [4-threonine]-oxytocin. More potent and specific oxytocic agent than oxytocin

22

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide

23

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

SOLID-PHASE PEPTIDE SYNTHESIS. 3. AN IMPROVED SYNTHESIS OF BRADYKININ

24

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin

26

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Eine neue Methode zur Synthese von Peptiden: Aktivierung der Carboxylgruppe mit Dicyclohexylcarbodiimid unter Zusatz von 1‐Hydroxy‐benzotriazolen

27

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors

30

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Synthetic metabolites of neurohypophyseal hormones. [Des-9-glycinamide]oxytocin and [des-9-glycinamide,des-8-leucine]oxytocin

31

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

THE SYNTHESIS OF AN OCTAPEPTIDE AMIDE WITH THE HORMONAL ACTIVITY OF OXYTOCIN

32

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

1-Deaminopenicillamine,4-threonineoxytocin, a potent inhibitor of oxytocin

34

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

1-(.beta.-Mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid),4-valine, 8-D-argininevasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin

35

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin

36

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Design and synthesis of potent in vivo antagonists of oxytocin

37

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin

38

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand

39

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15

43

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract

44

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

pA, a new scale for the measurement of drug antagonism

45

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

The quantitative assay of vasopressin

46

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Differences in the antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins

47

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues

48

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Influence of sarcosine or N-methylalanine in position 7 on the antagonistic properties of [1-deaminopenicillamine]- and [1-(β-mercapto-β, β-cyclopentylmethylene-propionic acid)]-vasopressin

49

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7

50

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

The syndrome of inappropriate secretion of antidiuretic hormone

51

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

1-.beta.-Mercapto-.beta.,.beta.-pentamethylenepropionic acidoxytocin, a potent inhibitor of oxytocin

52

1 reference

10.1002/PSC.310010109

https://api.crossref.org/works/10.1002/PSC.310010109

7 November 2024

Identifiers

10.1002/PSC.310010109

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9222985%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73510238&oldid=2271291339"